化合物简介
Elbasvir (MK-8742) is a drug approved (FDA Jan 2016) for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, following promising results in Phase II when used in combination with the NS3/4a protease inhibitor grazoprevir, either with or without ribavirin.
Elbasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5a replication complex. It has only been investigated as a combination product with other complementary hepatitis C antiviral drugs such as grazoprevir and MK-3682, and it is unclear whether elbasvir would show robust antiviral activity if it was administered by itself. Nevertheless, combination products of this type represent the most successful approach yet developed for actually curing hepatitis C, rather than merely slowing the progression of the disease.
Elbasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5a replication complex. It has only been investigated as a combination product with other complementary hepatitis C antiviral drugs such as grazoprevir and MK-3682, and it is unclear whether elbasvir would show robust antiviral activity if it was administered by itself. Nevertheless, combination products of this type represent the most successful approach yet developed for actually curing hepatitis C, rather than merely slowing the progression of the disease.
基本信息
- 英文名称：
- elbasvir
- 英文别名：
- MK-8742;
((2S,2’S)-((2S,2’S)-2,2′-(5,5′-((S)-6-phenyl-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate;
dimethyl N,N’-([(6S)-6-phenylindolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate;
Elbasvir(MK8742);
- CAS号：
- 1370468-36-2
- 分子式：
- C49H55N9O7
- 分子量：
- 882.01700
- 精确质量：
- 881.42200
- PSA：
- 188.80000
- LogP：
- 8.77360
